Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG. We show 13 historical shares outstanding datapoints in our RXRX shares outstanding history coverage, used to compute RXRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RXRX market cap history over the course of time is important for investors
interested in comparing RXRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RXRX versus a peer is one thing; comparing
RXRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RXRX can fluctuate over the course of history.
With this page we aim to empower investors researching RXRX by allowing them to research the RXRX market cap history. |
Free RXRX Email Alerts:
Video: The Importance of Market Cap
